A study showed that using measurable residual disease (MRD) to guide ibrutinib-venetoclax therapy significantly improved ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible resultsResults that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback